Featured Research

from universities, journals, and other organizations

Drug tests in humans for methamphetamine addiction

Date:
December 19, 2012
Source:
University of Arkansas for Medical Sciences
Summary:
Scientists have successfully completed dosing in the first human safety study of a medication to help methamphetamine users fight their addictions.

InterveXion Therapeutics LLC and the University of Arkansas for Medical Sciences (UAMS) have successfully completed dosing in the first human safety study of a medication to help methamphetamine users fight their addictions.

The medication is expected to significantly reduce or prevent the euphoric rush that drug users crave by keeping methamphetamine in the bloodstream and out of the brain, where the drug exerts its most powerful effects.

In the Phase I trial, 40 healthy volunteers who do not use methamphetamine received the medication over the past eight months and experienced no serious side effects.

"While we still have lots of work to do, this is a significant milestone for this research," said Brooks Gentry, M.D., a UAMS professor and InterveXion's chief medical officer who is overseeing the clinical trial phase. "Many experimental drugs fail during the first phase of a clinical trial, so we're excited that we can now look forward to testing in methamphetamine users who want help reducing their meth dependence."

When it has received final approval, the antibody will be given as an integral part of a methamphetamine user's complete treatment program, which consists of counseling and possibly other medications to reduce craving.

The medication, named ch-mAb7F9, is a monoclonal antibody. InterveXion, the trial sponsor, contracted the safety study to the Quintiles Phase 1 unit in Overland Park, Kan. The volunteers in the study, who received doses that ranged from 0.2 to 20 mg/kg, will continue to be followed for 21 weeks. Results of the Phase 1a study are expected in mid-2013.

The next steps in the development of the medication include further nonclinical safety testing followed by a Phase 1b clinical safety trial in current methamphetamine users.

Funding for the project was awarded to UAMS and InterveXion from the National Institute on Drug Abuse (NIDA). Additional support was given by the UAMS Translational Research Institute. NIDA has backed the development, manufacture and toxicology testing of this medication through previous grants to InterveXion and UAMS.

InterveXion, a UAMS BioVentures incubator client company, has licensed the technology for anti-methamphetamine antibody products from UAMS and is working closely with the university during product development.

Methamphetamine abuse has been a significant problem in the United States for the last decade. According to the Substance Abuse and Mental Health Services Administration, there were 439,000 methamphetamine users in the U.S. in 2011. New methamphetamine users numbered 133,000. In 2010, more than 100,000 were admitted to drug abuse treatment with methamphetamine as their primary substance of abuse. In addition, there were 54.9 emergency department visits per 100,000 population aged 21 or older involving methamphetamine use.


Story Source:

The above story is based on materials provided by University of Arkansas for Medical Sciences. Note: Materials may be edited for content and length.


Cite This Page:

University of Arkansas for Medical Sciences. "Drug tests in humans for methamphetamine addiction." ScienceDaily. ScienceDaily, 19 December 2012. <www.sciencedaily.com/releases/2012/12/121219092715.htm>.
University of Arkansas for Medical Sciences. (2012, December 19). Drug tests in humans for methamphetamine addiction. ScienceDaily. Retrieved July 25, 2014 from www.sciencedaily.com/releases/2012/12/121219092715.htm
University of Arkansas for Medical Sciences. "Drug tests in humans for methamphetamine addiction." ScienceDaily. www.sciencedaily.com/releases/2012/12/121219092715.htm (accessed July 25, 2014).

Share This




More Mind & Brain News

Friday, July 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

Beatings and Addiction: Pakistan Drug 'clinic' Tortures Patients

AFP (July 24, 2014) A so-called drugs rehab 'clinic' is closed down in Pakistan after police find scores of ‘patients’ chained up alleging serial abuse. Duration 03:05 Video provided by AFP
Powered by NewsLook.com
New Painkiller Designed To Discourage Abuse: Will It Work?

New Painkiller Designed To Discourage Abuse: Will It Work?

Newsy (July 24, 2014) The FDA approved Targiniq ER on Wednesday, a painkiller designed to keep users from abusing it. Like any new medication, however, it has doubters. Video provided by Newsy
Powered by NewsLook.com
Can Watching TV Make You Feel Like A Failure?

Can Watching TV Make You Feel Like A Failure?

Newsy (July 24, 2014) A study by German researchers claims watching TV while you're stressed out can make you feel guilty and like a failure. Video provided by Newsy
Powered by NewsLook.com
China's Ageing Millions Look Forward to Bleak Future

China's Ageing Millions Look Forward to Bleak Future

AFP (July 24, 2014) China's elderly population is expanding so quickly that children struggle to look after them, pushing them to do something unexpected in Chinese society- move their parents into a nursing home. Duration: 02:07 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

    Health News

      Environment News

        Technology News



          Save/Print:
          Share:

          Free Subscriptions


          Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

          Get Social & Mobile


          Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

          Have Feedback?


          Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
          Mobile: iPhone Android Web
          Follow: Facebook Twitter Google+
          Subscribe: RSS Feeds Email Newsletters
          Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins